nexalin technology is a non-invasive and drug-free therapy for those living with anxiety, depression and/or insomnia. nexalin’s patented waveform (1 u.s. patent #6904322b2) the nexalin device produces a patented waveform that provides transcranial electrical stimulation (tes). in clinical trials, this unique waveform resulted in the greatest increase in beta-endorphins. the nexalin device has undergone extensive safety analysis with the results clearly indicating that the device is safe for its intended use. additionally, the fda classification of the device for clinical trials places it into a non-significant risk (low risk device) category. natural frequency will promote balance in the brain by normalizing neurochemistry.this effectiveness of this unique therapy is long lasting and fda approved. laboratory and clinical evidence suggest that nexalin’s patented electrical stimulation affects the hypothalamus and related brain structures to adapt and change the levels of neurochemicals
Company profile
Ticker
NXL
Exchange
CEO
Peter Sohn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
IRS number
275566468
NXL stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
27 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
20 Mar 24
DEF 14A
Definitive proxy
16 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
DEF 14A
Definitive proxy
5 Oct 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Entry into a Material Definitive Agreement
2 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 361.40 k | 361.40 k | 361.40 k | 361.40 k | 361.40 k | 361.40 k |
Cash burn (monthly) | (no burn) | 625.22 k | 805.18 k | 399.29 k | 754.72 k | 366.05 k |
Cash used (since last report) | n/a | 3.72 mm | 4.79 mm | 2.37 mm | 4.49 mm | 2.18 mm |
Cash remaining | n/a | -3.36 mm | -4.43 mm | -2.01 mm | -4.13 mm | -1.82 mm |
Runway (months of cash) | n/a | -5.4 | -5.5 | -5.0 | -5.5 | -5.0 |
Institutional ownership, Q2 2023
10.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 94.44 mm |
Total shares | 765.82 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 325.00 k | $35.75 mm |
Warberg Asset Management | 166.48 k | $18.31 mm |
Altium Capital Management | 105.00 k | $11.55 mm |
Clear Street | 89.75 k | $10.00 k |
Walleye Capital | 39.04 k | $4.30 mm |
Citadel Advisors | 14.72 k | $1.45 mm |
Boothbay Fund Management | 13.50 k | $12.06 mm |
Tower Research Capital | 9.06 k | $8.10 mm |
UBS UBS Group AG - Registered Shares | 2.00 k | $1.79 mm |
MS Morgan Stanley | 1.26 k | $1.13 mm |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
21 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
14 Mar 24
Nexalin Technology Commences Sales Of Gen-2 Neurostimulation Device To New Mental Health Center In Oman Dedicated To Nexalin's Technology
14 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Mar 24
Press releases
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
14 Mar 24
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
8 Feb 24
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
23 Jan 24
Nexalin Technology Unveils Next-Generation HALO™ Clarity
11 Jan 24